scholarly journals ChoKs as a Promising Therapeutic Target for a Variety of Pathologies

2021 ◽  
Vol 4 (11) ◽  
pp. 256
Author(s):  
Salam A Ibrahim

Alterations in cell metabolism represent a common cause of human diseases. Changes in lipid profiles are not an exception to this rule, including those lipids that are produced via the choline kinase (ChoK) pathway. ChoK catalyzes the conversion of choline to phosphocholine via the transfer of a phosphate group from ATP to choline.

2020 ◽  
Vol 21 (1) ◽  
pp. 355 ◽  
Author(s):  
Anthea Di Rita ◽  
Teresa Maiorino ◽  
Krenare Bruqi ◽  
Floriana Volpicelli ◽  
Gian Carlo Bellenchi ◽  
...  

The selective elimination of dysfunctional mitochondria through mitophagy is crucial for preserving mitochondrial quality and cellular homeostasis. The most described mitophagy pathway is regulated by a positive ubiquitylation feedback loop in which the PINK1 (PTEN induced kinase 1) kinase phosphorylates both ubiquitin and the E3 ubiquitin ligase PRKN (Parkin RBR E3 ubiquitin ligase), also known as PARKIN. This event recruits PRKN to the mitochondria, thus amplifying ubiquitylation signal. Here we report that miR-218 targets PRKN and negatively regulates PINK1/PRKN-mediated mitophagy. Overexpression of miR-218 reduces PRKN mRNA levels, thus also reducing protein content and deregulating the E3 ubiquitin ligase action. In fact, following miR-218 overexpression, mitochondria result less ubiquitylated and the autophagy machinery fails to proceed with correct mitochondrial clearance. Since mitophagy defects are associated with various human diseases, these results qualify miR-218 as a promising therapeutic target for human diseases.


2021 ◽  
Vol 8 ◽  
Author(s):  
Rongsheng Xu ◽  
Huidan Tan ◽  
Jiahui Zhang ◽  
Zhaoxin Yuan ◽  
Qiang Xie ◽  
...  

Fam20C, a typical member of Fam20 family, has been well-known as a Golgi casein kinase, which is closely associated with Raine Syndrome (RS). It can phosphorylate many secreted proteins and multiple substrates, and thereby plays a crucial role in biological functions. More importantly, Fam20C has also been found to enhance the metastasis of several types of human cancers, such as breast cancer, indicating that Fam20C may be a promising therapeutic target. Accordingly, some small-molecule inhibitors of Fam20C have been reported in cancer. Taken together, these inspiring findings would shed new light on exploiting Fam20C as a potential therapeutic target and inhibiting Fam20C with small-molecule compounds would provide a clue on discovery of more candidate small-molecule drugs for fighting with human diseases.


2020 ◽  
Vol 245 (16) ◽  
pp. 1518-1528 ◽  
Author(s):  
Xiaopeng Cai ◽  
Jingwen Deng ◽  
Qianqian Ming ◽  
Huiqiang Cai ◽  
Zhi Chen

Chemokines are a family of small molecular-weight proteins, being well-known with their important roles in the process of allergic response, immune regulation, cell proliferation, and differentiation. Almost two decades ago, a novel member of this family, chemokine-like factor 1 (CKLF1) was identified. In recent years, it draws much attention of researchers because of its key roles in many types of tissues and its potential implications in a large number of diseases. Up to now, CKLF1 has been shown to have two main functions: broad-spectrum chemotactic activity, and proliferation- and differentiation-promoting abilities. In this review, we would introduce the basic structural features of CKLF1 and its biological functions, and then elaborate the relationships between CKLF1 and human diseases. The cell signaling pathways CKLF1 may be involved in would be discussed and summarized in details. Furthermore, we present the trials of CKLF1-targeted treatments in animal disease models, hoping to provide a few important insights about CKLF1 to both medical researchers and pharmacy, and finally conclude that CKLF1 is a potent, and very promising, therapeutic target. Impact statement CKLF1, a recently identified chemokine, has been reported by a number of studies to play important roles in quite many diseases. However, the potential pathways that CKLF1 may be involved are not manifested well yet. In our review, we showed the basic molecular structure and major functions of this novel chemokine, and implication in human diseases, such as tumors. To attract more attention, we summarized its signaling pathways and clearly present them in a set of figures. With the overview of the experimental trial of CKLF1-targeting medicines in animal models, we hope to provide a few important insights about CKLF1 to both medical researchers and pharmacy.


2019 ◽  
Author(s):  
Silvia Scaricamazza ◽  
Illari Salvatori ◽  
Giacomo Giacovazzo ◽  
Jean Philippe Loeffler ◽  
Frederique Renè ◽  
...  

2021 ◽  
Author(s):  
Johannes Burtscher ◽  
Muhammed Muazzam Kamil Syed ◽  
Hilal A. Lashuel ◽  
Grégoire P. Millet

Author(s):  
Marco Spreafico ◽  
Alicja M. Gruszka ◽  
Debora Valli ◽  
Mara Mazzola ◽  
Gianluca Deflorian ◽  
...  

2014 ◽  
Vol 18 (4) ◽  
pp. 403-414 ◽  
Author(s):  
Shinya Matsuzaki ◽  
Satoshi Serada ◽  
Akiko Morimoto ◽  
Yutaka Ueda ◽  
Kiyoshi Yoshino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document